Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) delivers vital blood and plasma management solutions to healthcare providers worldwide. This page serves as the definitive source for official company announcements, financial updates, and innovation milestones.
Access timely updates on earnings reports, regulatory clearances, and strategic partnerships that shape HAE's leadership in medical technology. Investors will find press releases covering product launches like advanced diagnostic systems, operational expansions, and initiatives enhancing transfusion safety standards.
Our curated news collection helps stakeholders monitor developments across HAE's three core segments: plasma collection technologies, blood center optimization tools, and hospital transfusion management systems. Bookmark this page for direct access to filings, executive commentary, and progress updates on life-saving healthcare solutions.
Haemonetics Corporation (NYSE: HAE) has announced the schedule for its fourth quarter and fiscal year 2023 financial results. The results will be published on May 11, 2023, at 6:00 am ET, followed by a conference call with investors and analysts at 8:00 am ET the same day. Investors can access the call via a teleconference link provided in the announcement. Additionally, a live webcast will be available on the Haemonetics investor relations website. A replay of the call will be accessible for one year after the event. Haemonetics focuses on innovative medical products aimed at improving patient care and reducing healthcare costs, particularly in blood and plasma component collection and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced the release of its first Corporate Responsibility Report on April 20, 2023. The report outlines the company's progress in environmental, social, and governance (ESG) initiatives for the fiscal year 2022, concluding on April 2, 2022. Key highlights include:
- Human capital initiatives aimed at attracting a diverse workforce.
- Results from the company's first greenhouse gas emissions assessment.
- Information on corporate governance, ethics, product safety, and cybersecurity.
CEO Christopher A. Simon emphasized the importance of addressing ESG risks and maintaining stakeholder trust. The report is available on Haemonetics' website.
Vivasure Medical announced its pivotal PATCH Clinical Study for the PerQseal® Closure Device has received FDA Investigational Device Exemption (IDE) approval. The study will enroll up to 188 patients in the U.S. and Europe, aiming for FDA pre-market approval and commercial launch by year-end 2023. The company also secured a €30 million strategic investment from Haemonetics as part of its Series D financing, with an option for acquisition upon milestone completion. The global market for large hole vessel closure is valued at over $300 million, with strong growth potential, emphasizing the significance of this partnership and study.
Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug Administration for its next-generation Intelligent Control software for the Cell Saver Elite+ Autotransfusion System. This upgrade includes over 50 automation enhancements aimed at improving efficiency and user experience. The Cell Saver technology allows hospitals to recover patients' blood during surgeries, helping prevent unnecessary transfusions. The software upgrade enhances versatility, offering features such as Manual Mode and optimized wash volumes according to industry standards.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
